We are experienced in valuing biotech companies. We understand value at stages, patient cliff and spin-offs based on patents. Our valuations are recognized by the IRS, SBA, banks and merger and acquisition professionals. We perform valuations of 100% of the company and of non-controlling, minority shares. We are accredited by the National Association of Certified Analysts (NACVA), a credential that requires demonstrated business experience, training, continuing education and peer review of a case study prior to credentialing.